Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.35 USD | +2.75% | -3.64% | -9.29% |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
Mar. 29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 17.41M |
---|---|---|---|---|---|
Net income 2024 * | -40M | Net income 2025 * | -42M | EV / Sales 2024 * | - |
Net Debt 2024 * | 2.46M | Net cash position 2025 * | 39.69M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.61
x | P/E ratio 2025 * |
-0.54
x | Employees | 43 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.05% |
1 day | +1.62% | ||
1 week | -3.64% | ||
Current month | -20.33% | ||
1 month | -19.42% | ||
3 months | -10.81% | ||
6 months | -14.07% | ||
Current year | -9.29% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Iwicki
CEO | Chief Executive Officer | 57 | 15-02-28 |
Mary Reumuth
DFI | Director of Finance/CFO | 48 | 14-01-31 |
Todd Bazemore
PSD | President | 53 | 17-11-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Koven
BRD | Director/Board Member | 66 | 17-09-27 |
Gregory Perry
BRD | Director/Board Member | 63 | 18-03-04 |
Howard Rosen
BRD | Director/Board Member | 66 | 14-01-05 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 6.35 | +2.75% | 1 417 |
24-04-25 | 6.18 | -3.44% | 8,260 |
24-04-24 | 6.4 | -2.53% | 1,101 |
24-04-23 | 6.566 | +3.73% | 5,284 |
24-04-22 | 6.33 | -3.95% | 12,630 |
Delayed Quote Nasdaq, April 26, 2024 at 11:09 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.29% | 17.41M | |
+25.77% | 653B | |
+27.00% | 556B | |
-6.55% | 354B | |
+20.33% | 331B | |
+3.01% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.33% | 144B |
- Stock Market
- Equities
- KALA Stock